Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
65 hedge funds and large institutions have $52.2M invested in Infinity Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 27 reducing their positions, and 12 closing their positions.
257% more call options, than puts
Call options by funds: $300K | Put options by funds: $84K
43% more capital invested
Capital invested by funds: $36.6M → $52.2M (+$15.6M)
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
3% more funds holding
Funds holding: 63 → 65 (+2)
59% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.44M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$3.94M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$2.43M |
| 4 |
Millennium Management
New York
|
+$1.28M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$676K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.17M |
| 2 |
O
OrbiMed
New York
|
-$2.94M |
| 3 |
Renaissance Technologies
New York
|
-$1.85M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.55M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$942K |
INFI Hedge Fund Activity: Q4 2017 in Review
65 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2017, worth a combined $52.2M — up 43% from $36.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new INFI positions and 12 closed out — a net gain of 2 holders — while 11 added to existing stakes and 27 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $7.44M. The largest seller was Wellington Management Group, cutting an estimated $9.17M.
- 65 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2017, up from 63 in Q3 2017.
- Funds reported $52.2M of Infinity Pharmaceuticals, Inc. stock for Q4 2017, up 43% quarter-over-quarter.
- 14 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2017 and 12 closed out, a net change of +2 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2017 was Fidelity Investments, an estimated $7.44M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q4 2017 was Wellington Management Group, an estimated $9.17M sold.
Based on aggregated 13F filings for Q4 2017.